Gain-of-function mutation reveals new target in pediatric acute myeloid leukemia
Pediatric acute myeloid leukemia (AML) accounts for 20% of all pediatric leukemia cases and is associated with poor outcomes, especially if the disease relapses. Part of the struggle with treating pediatric AML is that the current understanding and interventions stem primarily from knowledge of adult AML, which differs from pediatric disease. However, St. Jude scientists are working to change this.
Comentarios